2. Search Result
Search Result
Results for "

ventricular hypertrophy

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Peptides

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0259
    Indapamide
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
    Indapamide
  • HY-B0419
    Manidipine
    3 Publications Verification

    		 Calcium Channel Interleukin Related Cardiovascular Disease Neurological Disease Endocrinology
    Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy .
    Manidipine
  • HY-B0424
    Nitrendipine
    3 Publications Verification

    BAY-E-5009

    		 Calcium Channel Apoptosis Cardiovascular Disease Neurological Disease Cancer
    Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .
    Nitrendipine
  • HY-W042301
    Xipamide

    		Anion Exchangers Carbonic Anhydrase Endothelin Receptor Cardiovascular Disease
    Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na +/Cl --potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl -/NaCO3 - anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca 2+ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .
    Xipamide
  • HY-172424
    Delocamten

    		Myosin Cardiovascular Disease
    Delocamten is the inhibitor for cardiac myosin with an IC50 of 1.1 μM. Delocamten can be used in researchs of hypertrophic cardiomyopathy, left ventricular hypertrophy and diastolic dysfunction .
    Delocamten
  • HY-B0424S
    Nitrendipine-d5

    AY-E-5009-d5

    		 Isotope-Labeled Compounds Calcium Channel Apoptosis Cardiovascular Disease Neurological Disease Cancer
    Nitrendipine-d5 is the deuterium labeled Nitrendipine (HY-B0424). Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .
    Nitrendipine-d5
  • HY-114683
    KS370G

    		TGF-beta/Smad Cardiovascular Disease
    KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy .
    KS370G
  • HY-B0259R
    Indapamide (Standard)
    1 Publications Verification

    		 Reference Standards Potassium Channel Cardiovascular Disease
    Indapamide (Standard) is the analytical standard of Indapamide. This product is intended for research and analytical applications. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
    Indapamide (Standard)
  • HY-B0424R
    Nitrendipine (Standard)

    BAY-E-5009 (Standard)

    		 Reference Standards Calcium Channel Apoptosis Cardiovascular Disease Neurological Disease Cancer
    Nitrendipine (Standard) is the analytical standard of Nitrendipine (HY-B0424). This product is intended for research and analytical applications. Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .
    Nitrendipine (Standard)
  • HY-106994A
    Nebentan potassium

    YM598

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan potassium
  • HY-116478
    L-3373

    		Potassium Channel Others
    L-3373 is a voltage-dependent potassium channel inhibitor with activity that reduces the effective refractory period and the dispersion of monophasic action potential duration, while significantly reducing susceptibility to ventricular fibrillation in a cat model of left ventricular hypertrophy.
    L-3373
  • HY-B0259S
    (rac)-Indapamide-d3

    		Isotope-Labeled Compounds Potassium Channel Cardiovascular Disease
    (rac)-Indapamide-d3 is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
    (rac)-Indapamide-d3
  • HY-P11297
    AC-SDKP-NH2

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research .
    AC-SDKP-NH2
  • HY-B0259A
    Indapamide hemihydrate

    		Potassium Channel Cardiovascular Disease
    Indapamide hemihydrate is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide hemihydrate is also can reduce left ventricular hypertrophy .
    Indapamide hemihydrate
  • HY-159484
    Hsp110/sGC-modulator-1

    		HSP Guanylate Cyclase Cardiovascular Disease
    Hsp110/sGC-modulator-1 (compound 17i), an orally active Hsp110/sGC dual-target regulator, exhibits optimal Hsp110 and sGC molecular activities as well as remarkable cell malignant phenotypes inhibitory and vasodilatory effects. Hsp110/sGC-modulator-1 (compound 17i) attenuates pulmonary vascular remodeling and right ventricular hypertrophy via Hsp110 suppression .
    Hsp110/sGC-modulator-1
  • HY-B0419R
    Manidipine (Standard)

    		Calcium Channel Interleukin Related Reference Standards Cardiovascular Disease Neurological Disease Endocrinology
    Manidipine (Standard) is the analytical standard of Manidipine. This product is intended for research and analytical applications. Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy .
    Manidipine (Standard)
  • HY-120298
    LY-510929

    		PPAR Others
    LY-510929 is a compound that induces left ventricular hypertrophy (LVH). Related studies have identified the relevant conditions in which LY-510929 may induce LVH by measuring multiple markers and using multiple techniques.
    LY-510929
  • HY-B0259S3
    Indapamide-d6

    		Isotope-Labeled Compounds Potassium Channel Cardiovascular Disease
    Indapamide-d6 is a deuterated labeled Indapamide . Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
    Indapamide-d6
  • HY-B0259S1
    Indapamide-13C,d3

    		Isotope-Labeled Compounds Potassium Channel Cardiovascular Disease
    Indapamide- 13C,d3 is 13C and deuterium labeled Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
    Indapamide-13C,d3
  • HY-118264
    MDL-100240

    		Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease
    MDL-100240 is a dual-acting angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. MDL-100240 can significantly lower blood pressure, reverse left ventricular hypertrophy, and effectively prevent hypertrophy and dilatation of the aorta and resistance arteries, with an effect comparable to that of ramipril (HY-B0279). In addition, MDL-100240 can also reduce aldosterone levels, but has no significant effect on atrial natriuretic peptide and cGMP. In 3-month-old transgenic rats, MDL-100240 can reduce adrenomedullin concentrations, prevent and reverse severe hypertension and cardiovascular damage, and enhance bradykinin effects.
    MDL-100240
  • HY-115477
    Brilaroxazine hydrochloride

    RP5063 hydrochloride

    		 5-HT Receptor Cardiovascular Disease
    Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.
    Brilaroxazine hydrochloride
  • HY-W700639
    Tolafentrine

    		Phosphodiesterase (PDE) Neurological Disease
    Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes .
    Tolafentrine
  • HY-B0419S
    Manidipine-d4

    		Isotope-Labeled Compounds Calcium Channel Interleukin Related Cardiovascular Disease Neurological Disease
    Manidipine-d4 is the deuterium labeled Manidipine (HY-B0419). Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy .
    Manidipine-d4
  • HY-106994
    Nebentan

    YM598 free base

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan
  • HY-183644
    LNO 9

    		Lysyl Oxidase Cardiovascular Disease
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
    LNO 9
  • HY-103084
    PDE5-IN-1

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-1 (compound 2) is a PDE5 inhibitor with an IC50 of 5.6 nM and oral bioavailability. PDE5-IN-1 forms hydrogen bond interactions with the Q817 residue in the catalytic domain of PDE5, and aromatic π-π stacking interactions with the F820 residue. PDE5-IN-1 exerts anti-cardiac hypertrophy and vasodilatory effects, reduces mean pulmonary arterial pressure and right ventricular hypertrophy index. PDE5-IN-1 can be used in the research of pulmonary arterial hypertension .
    PDE5-IN-1
  • HY-106994AR
    Nebentan potassium (Standard)

    YM598 (Standard)

    		 Reference Standards Endothelin Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Nebentan potassium (Standard) (GT-2331 maleate (Standard)) is the analytical standard of Nebentan (potassium) (HY-106994A). This product is intended for research and analytical applications. Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan potassium (Standard)
  • HY-182642
    MRS2339

    		P2X Receptor Nucleoside Antimetabolite/Analog Cardiovascular Disease
    MRS2339 is a ribose-modified nucleotide and a nucleotidase-resistant P2 receptor agonist. MRS2339 activates P2X4R. MRS2339 induces ionic currents via P2X receptors, reduces cardiomyocyte cross-sectional area and heart weight/body weight ratio, lacks vasodilatory activity, and extends the lifespan of mice with cardiomyopathy. MRS2339 can be used in research related to heart failure and cardiomyopathy .
    MRS2339

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: